MARKSANS PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 256.23 INR | -2.61% |
|
+6.87% | +59.22% |
| Aug. 21 | Marksans Pharma Arm Gets UK Regulator's Marketing Nod for Fluoxetine Capsules | MT |
| Aug. 20 | Marksans Pharma Gets US FDA's EIR for Goa, India Unit | MT |
Projected Income Statement: Marksans Pharma Limited
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| Net sales 1 | - | 21,774 | 26,418 | 31,110 | 35,690 |
| Change | - | - | 21.33% | 17.76% | 14.72% |
| EBITDA 1 | - | 4,586 | 5,534 | 6,771 | 8,207 |
| Change | - | - | 20.68% | 22.35% | 21.21% |
| EBIT 1 | - | - | 5,023 | 6,228 | 7,248 |
| Change | - | - | - | 23.98% | 16.39% |
| Interest Paid 1 | - | -112.3 | -114.7 | -110.3 | -118 |
| Earnings before Tax (EBT) 1 | - | 4,235 | 5,173 | 6,466 | 8,018 |
| Change | - | - | 22.14% | 24.99% | 24.02% |
| Net income 1 | 2,653 | 3,137 | 3,859 | 4,823 | 5,974 |
| Change | - | 18.23% | 23% | 25% | 23.85% |
| Announcement Date | 5/30/23 | 5/30/24 | - | - | - |
1INR in Million
Estimates
Forecast Balance Sheet: Marksans Pharma Limited
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | -8,418 | -10,622 | -13,408 |
| Change | - | - | - | -226.18% | -226.23% |
| Announcement Date | 5/30/23 | 5/30/24 | - | - | - |
1INR in Million
Estimates
Cash Flow Forecast: Marksans Pharma Limited
| Fiscal Period: March | 2025 | 2026 | 2027 |
|---|---|---|---|
| CAPEX 1 | 1,225 | 1,000 | 1,000 |
| Change | - | -18.37% | 0% |
| Free Cash Flow (FCF) 1 | 2,024 | 3,460 | 4,354 |
| Change | - | 70.88% | 25.86% |
| Announcement Date | - | - | - |
1INR in Million
Estimates
Forecast Financial Ratios: Marksans Pharma Limited
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
Profitability | |||||
| EBITDA Margin (%) | - | 21.06% | 20.95% | 21.76% | 23% |
| EBIT Margin (%) | - | - | 19.01% | 20.02% | 20.31% |
| EBT Margin (%) | - | 19.45% | 19.58% | 20.78% | 22.47% |
| Net margin (%) | - | 14.41% | 14.61% | 15.5% | 16.74% |
| FCF margin (%) | - | - | 7.66% | 11.12% | 12.2% |
| FCF / Net Income (%) | - | - | 52.47% | 71.72% | 72.89% |
Profitability | |||||
| ROA | - | - | - | - | - |
| ROE | - | 16.47% | 16.37% | 17.67% | 19.45% |
Financial Health | |||||
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - |
Capital Intensity | |||||
| CAPEX / Current Assets (%) | - | - | 4.64% | 3.21% | 2.8% |
| CAPEX / EBITDA (%) | - | - | 22.14% | 14.77% | 12.18% |
| CAPEX / FCF (%) | - | - | 60.51% | 28.91% | 22.97% |
Items per share | |||||
| Cash flow per share 1 | - | - | - | - | - |
| Change | - | - | - | - | - |
| Dividend per Share 1 | - | - | 0.7 | 2.7 | 3.3 |
| Change | - | - | - | 285.71% | 22.22% |
| Book Value Per Share 1 | - | 45.57 | 53.4 | 62 | 69.9 |
| Change | - | - | 17.18% | 16.1% | 12.74% |
| EPS 1 | 6.41 | 6.92 | 8.533 | 10.63 | 13.2 |
| Change | - | 7.96% | 23.31% | 24.61% | 24.14% |
| Nbr of stocks (in thousands) | 453,164 | 453,164 | 453,164 | 453,164 | 453,164 |
| Announcement Date | 5/30/23 | 5/30/24 | - | - | - |
1INR
Estimates
| 2025 * | 2026 * | |
|---|---|---|
| P/E ratio | 30.8x | 24.7x |
| PBR | 4.93x | 4.24x |
| EV / Sales | 4.19x | 3.49x |
| Yield | 0.27% | 1.03% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
263.09INR
Average target price
261.33INR
Spread / Average Target
-0.67%
Annual profits - Rate of surprise
- Stock Market
- Equities
- MARKSANS Stock
- Financials Marksans Pharma Limited